0001209191-18-054716.txt : 20181010
0001209191-18-054716.hdr.sgml : 20181010
20181010180257
ACCESSION NUMBER: 0001209191-18-054716
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181008
FILED AS OF DATE: 20181010
DATE AS OF CHANGE: 20181010
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vaughn James J
CENTRAL INDEX KEY: 0001649689
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51541
FILM NUMBER: 181116825
MAIL ADDRESS:
STREET 1: C/O GENOMIC HEALTH, INC.
STREET 2: 301 PENOBSCOT DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GENOMIC HEALTH INC
CENTRAL INDEX KEY: 0001131324
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 770552594
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 301 PENOBSCOT DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
BUSINESS PHONE: 650-556-9300
MAIL ADDRESS:
STREET 1: 301 PENOBSCOT DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-10-08
0
0001131324
GENOMIC HEALTH INC
GHDX
0001649689
Vaughn James J
301 PENOBSCOT DRIVE
REDWOOD CITY
CA
94063
0
1
0
0
Chief Commercial Officer
Common Stock
2018-10-08
4
M
0
3732
28.05
A
21274
D
Common Stock
2018-10-08
4
M
0
18110
30.84
A
39384
D
Common Stock
2018-10-08
4
M
0
2838
31.12
A
42222
D
Common Stock
2018-10-08
4
M
0
320
27.00
A
42542
D
Common Stock
2018-10-08
4
S
0
16215
64.976
D
26327
D
Common Stock
2018-10-08
4
S
0
6310
65.8155
D
20017
D
Common Stock
2018-10-08
4
S
0
2475
66.5197
D
17542
D
Common Stock
2018-10-09
4
M
0
5653
27.48
A
23195
D
Common Stock
2018-10-09
4
M
0
2390
31.12
A
25585
D
Common Stock
2018-10-09
4
M
0
16957
27.00
A
42542
D
Common Stock
2018-10-09
4
S
0
19270
64.2293
D
23272
D
Common Stock
2018-10-09
4
S
0
5730
64.8563
D
17542
D
Employee Stock Option (right to buy)
28.05
2018-10-08
4
M
0
3732
0.00
D
2023-01-31
Common Stock
3732
0
D
Employee Stock Option (right to buy)
30.84
2018-10-08
4
M
0
18110
0.00
D
2024-01-28
Common Stock
18110
0
D
Employee Stock Option (right to buy) Holding
31.12
2018-10-08
4
M
0
2838
0.00
D
2025-02-13
Common Stock
2838
42162
D
Employee Stock Option (right to buy) Holding
31.12
2018-10-09
4
M
0
2390
0.00
D
2025-02-13
Common Stock
2390
39772
D
Employee Stock Option (right to buy) Holding
27.00
2018-10-08
4
M
0
320
0.00
D
2026-02-16
Common Stock
320
41380
D
Employee Stock Option (right to buy) Holding
27.00
2018-10-09
4
M
0
16957
0.00
D
2026-02-16
Common Stock
16957
24423
D
Employee Stock Option (right to buy) Holding
27.48
2018-10-09
4
M
0
5653
0.00
D
2027-01-31
Common Stock
5653
34927
D
Includes an aggregate of 15,534 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 6, 2018.
Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
Represents weighted average sale price. Actual sale prices ranged from $64.37 to $65.34.
Represents weighted average sale price. Actual sale prices ranged from $65.37 to $66.36.
Represents weighted average sale price. Actual sale prices ranged from $66.37 to $66.76.
Represents weighted average sale price. Actual sale prices ranged from $63.57 to $64.56.
Represents weighted average sale price. Actual sale prices ranged from $64.57 to $65.27.
The option became exercisable as to 25% of the shares on January 31, 2014, and became exercisable as to 1/48th of the shares each full month thereafter.
The option became exercisable as to 25% of the shares on January 28, 2015, and became exercisable as to 1/48th of the shares each full month thereafter.
The option becomes exercisable as to 25% of the shares on February 13, 2016, and becomes exercisable as to 1/48th of the shares each full month thereafter.
The option became exercisable as to 25% of the shares on February 16, 2017, and becomes exercisable as to 1/48th of the shares each full month thereafter.
The option became exercisable as to 25% of the shares on January 31, 2018, and becomes exercisable as to 1/48th of the shares each full month thereafter.
/s/ Jason W. Radford, Attorney-in-fact
2018-10-10